Grace Therapeutics Financials - Benzinga

Grace Therapeutics Inc

GRCENASDAQ

Trade with Public

Trade with Public

$2.13

0.010.47%

At close: Aug 6, 5:00 PM EST

$2.17

0.04612.17%

Pre-Market: 4:00 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Compare Options Stock Report

Grace Therapeutics Financials

Grace Therapeutics (GRCE) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Grace Therapeutics Q4 EPS $(0.06) Beats $(0.15) Estimate

Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.15) by 60 percent. This is a 160 percent decrease over earnings of $0.10 per share from the

Benzinga Newsdesk

PRO
Grace Therapeutics Q3 EPS $(0.14) Beats $(0.28) Estimate

Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.28) by 50 percent. This is a 61.11 percent increase over losses of $(0.36) per share from

Benzinga Newsdesk

PRO
Grace Therapeutics Q2 EPS $(0.06) Beats $(0.18) Estimate

Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.18) by 67.57 percent. This is a 80 percent increase over losses of $(0.30) per share from

Benzinga Newsdesk

PRO
Grace Therapeutics Q1 EPS $(0.21) Beats $(0.22) Estimate

Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.22) by 4.55 percent.

Benzinga Newsdesk

PRO
Grace Therapeutics Q3 EPS $(0.36) Vs $(0.34) Estimate

Benzinga Newsdesk

PRO
Grace Therapeutics Q2 2025 GAAP EPS $(0.30) Beats $(0.44) Estimate

Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.44) by 31.82 percent.

Benzinga Newsdesk